Novo Nordisk has gone up another gear in its drive to boost manufacturing capacity for its fast-growing GLP-1 agonist drugs, announcing plans to build a $4.1 billion fill-and-finish facilit
Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).
Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product.
Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t
Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) will be an option for many more patients in the US after the FDA expanded the breadth of its approved labelling.
Vanda Pharmaceuticals' board is unimpressed with takeover offers from both Cycle Pharma and Future Pak, saying they both “substantially undervalue” the company.